**Supplemental Figure S1. CONSORT diagram**

Intention-to-treat population (*n* = 40)
Safety set (*n* = 39)

Intention-to-treat population (*n* = 82)
Safety set (*n* = 82)

Assessed for eligibility (*n* = 147)

Excluded (*n* = 25)

* Not meeting inclusion criteria (*n* = 23)
* Declined to participate (*n* = 2)

Allocated to spartalizumab (*n* = 82)

* Received treatment (*n* = 82)
* Did not receive treatment (*n* = 0)

Allocated to chemotherapy (*n* = 40)

* Received treatment (*n* = 39)
* Did not receive treatment due to physician’s decision (*n* = 1)

Discontinued spartalizumab due to

* Progressive disease (*n* = 52)
* Death (*n* = 4)
* Physician’s decision (*n* = 1)
* Patient/guardian’s decision (*n* = 1)
* Adverse event (*n* = 1)

Discontinued chemotherapy due to

* Progressive disease (*n* = 32)
* Death (*n* = 2)
* Physician’s decision (*n* = 1)
* Patient/guardian’s decision (*n* = 2)
* Adverse event (*n* = 0)

Randomization (*n* = 122)

Allocation

Follow-up

Analysis